Table 5.
Ex vivo ADCC assays from patients enrolled in phase II trial
| Genotype | Media (−) | IgG (−) | Cetuximab | K562 (+) |
|---|---|---|---|---|
| VF | 11% | 9% | 25% | 17% |
| VV | 0% | 0% | 15% | 1 |
| FF | 9% | 1% | 3% | 0 |
| FF | 6% | 5% | 8% | 4 |
| VF | 7% | 5% | 11% | 7 |
| VF | 2% | 4% | 10% | 8 |
| FF | 8% | 6% | 54% | 32 |
| VF | 2% | 1% | 12% | 14 |
| VF | 6% | 6% | 3% | 2 |
| VF | 0% | 4% | 34% | 30 |
| VF | 4% | 4% | 33% | 28 |
| FF | 1% | 0% | 16% | 3 |
| FF | 4% | 5% | 54% | 47 |
| FF | 8% | 9% | 38% | 30 |
| FF | 5% | 7% | 11% | 12 |
| FF | 8% | 2% | 3% | 6 |
| FF | 3% | 3% | 2% | 2 |
| VF | 3% | 1% | 46% | 49 |
| VF | 0% | 8% | 17% | 6 |
| VF | 4% | 3% | 0% | 2 |
| VF | 11% | 1% | 23% | 19 |
| VF | 0% | 0% | 19% | 21 |
| FF | 12% | 4% | 13% | 8 |
| VF | 9% | 5% | 31% | 51 |
| VF | 6% | 7% | 41% | 51 |
NOTE: Results from ex vivo chromium-51 ADCC assays performed for 25 patients from phase II trial when adequate sample was available. First column indicates FcγRIIIa genotype, subsequent columns represent percentage of specific cell lysis for negative controls (media and IgG), cetuximab, and positive controls (K562), respectively. Bold rows indicate ADCC-inducible ex vivo assays.